4.3 Article

Taspoglutide, a once-weekly glucagon-like peptide 1 analogue, vs. insulin glargine titrated to target in patients with Type 2 diabetes: an open-label randomized trial

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Editorial Material Medicine, General & Internal

Rosiglitazone no longer recommended

[Anonymous]

LANCET (2008)

Article Medicine, General & Internal

Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes - A randomized trial

RJ Heine et al.

ANNALS OF INTERNAL MEDICINE (2005)